SyntheticMR Receives Regulatory Approval for SyMRI in Taiwan
SyntheticMR announced today that its quantitative imaging software solution, SyMRI 12, has received regulatory approval from the Taiwan Food and Drug Administration (TFDA). This milestone enables the sale and distribution of SyMRI 12 in the Taiwanese market, paving the way for regional expansion.
Dela artikeln
Taggar: syntheticmr, receives, regulatory
Läs vidare på Dagens IndustriRelaterade nyheter
- SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR’s SyMRI...
- SyntheticMR receives FDA 510(k) clearance for their next Generation Solution SyMRI 3D
- Philips teams with SyntheticMR to deliver breakthrough AI-based quantitative brain imaging in MR to advance neurology care for patients
- SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking
- SyntheticMR and Philips Announce Expanded Global Partnership for SyMRI 3D
Fler ekonominyheter
- SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR’s SyMRI...
- SyntheticMR receives FDA 510(k) clearance for their next Generation Solution SyMRI 3D
- Philips teams with SyntheticMR to deliver breakthrough AI-based quantitative brain imaging in MR to advance neurology care for patients
- SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking
- SyntheticMR and Philips Announce Expanded Global Partnership for SyMRI 3D